AM3, A NEW ORAL ROUTE BIOLOGICAL MODIFIER - PHARMACOLOGICAL AND CLINICAL ASPECTS

被引：0
|
作者：
TUDURI, P
VELASCO, R
MARTINEZ, A
GUERRERO, A
PIVEL, JP
VILLARRUBIA, VG
SADA, G
机构：
[1] ANDROMACO LABS,DEPT RES,MADRID,SPAIN
[2] ANDROMACO LABS,DEPT MED,MADRID,SPAIN
来源：
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1985年 / 7卷 / 03期
关键词：
D O I：
10.1016/0192-0561(85)90190-0
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] Clinical pharmacological aspects of new oral anticoagulants
    Haschke, Manuel
    THERAPEUTISCHE UMSCHAU, 2012, 69 (11) : 657 - 660
  • [2] The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis
    Albillos, Agustin
    Nieto, Monica
    Ubeda, Maria
    Munoz, Leticia
    Fraile, Benito
    Reyes, Eduardo
    Lledo, Lourdes
    Blanco, Ignacio
    Pastor, Oscar
    Salas, Clara
    Lario, Margaret
    Monserrat, Jorge
    Bataller, Ramon
    Alvarez-Mon, Melchor
    GUT, 2010, 59 (07) : 943 - 952
  • [3] AM3 (AN ORAL BIOLOGICAL RESPONSE MODIFIER) IN THE TREATMENT OF RECURRENT APHTHOUS STOMATITIS (RAS) - CLINICAL-EVALUATION AND PRELIMINARY STUDIES ON NK-(CD16) CELLS AND ITS PATHOGENIC ROLE IN RAS
    CAMACHO, F
    ELORZA, FL
    ORTEGA, M
    ELORZA, MA
    SADA, G
    VILLARRUBIA, VG
    REVISTA CLINICA ESPANOLA, 1991, 188 (08): : 403 - 408
  • [4] THE BIOLOGICAL RESPONSE MODIFIER AM3 ATTENUATES THE LIVER AND PERIPHERAL BLOOD INFLAMMATORY IMMUNE SYSTEM ACTIVATION AND REDUCES HEPATIC FIBROSIS IN RATS WITH BILIARY CIRRHOSIS
    Albillos, A.
    Nieto, M.
    Ubeda, M.
    Munoz, L.
    Fraile, B.
    Reyes, E.
    Lledo, L.
    Blanco, I.
    Salas, C.
    Lario, M.
    Monserrat, J.
    Bataller, R.
    Alvarez-Mon, M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S201 - S202
  • [5] The new antiepileptic drugs: Pharmacological and clinical aspects
    Gatti, G
    Bonomi, I
    Jannuzzi, G
    Perucca, E
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (08) : 839 - 860
  • [6] PHARMACOLOGICAL AND CLINICAL ASPECTS IN DEVELOPMENT OF NEW ANTIDEPRESSANTS
    AMREIN, R
    SCHMIDBURGK, W
    CURRENT MEDICAL RESEARCH AND OPINION, 1989, 11 : 53 - 64
  • [7] CLINICAL PHARMACOLOGICAL AND BIOPHARMACEUTICAL ASPECTS OF THE ORAL-ADMINISTRATION OF DRUGS
    MERKUS, FWHM
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1984, 6 (04) : 164 - 164
  • [8] The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3
    Villarrubia, VG
    MorenoKoch, M
    Calvo, C
    Gonzalez, S
    AlvarezMon, M
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1997, 19 (01) : 53 - 74
  • [9] Tetracyclic antidepressants: Pharmacological and clinical aspects and new developments
    Demling, J
    NERVENHEILKUNDE, 1996, 15 (02) : 92 - 100
  • [10] AM3, A NEW ANTAGONIST OF LIPOPOLYSACCHARIDE (LPS) INDUCED TUMOR-NECROSIS-FACTOR (TNF) PRODUCTION
    ALONSO, JL
    MOREJON, M
    PIVEL, JP
    IMMUNOBIOLOGY, 1987, 175 (1-2) : 124 - 125
12345